BACKGROUND: Since 2002, the US Food and Drug Administration has approved 6 rapid human immunodeficiency virus (HIV) tests for use in the United States. To date, there has been no direct comparison of the performance of all 6 tests. METHODS: Persons known to be HIV-infected and persons who sought HIV testing at 2 clinical sites in Los Angeles, California, were recruited for evaluation of 6 rapid HIV tests with whole blood, oral fluid, serum, and plasma specimens. Sensitivity and specificity of the rapid tests were compared with viral lysate and immunoglobulin (Ig) M-sensitive peptide HIV enzyme immunoassays (EIAs). RESULTS: A total of 6282 specimens were tested. Sensitivity was >95% and specificity was >99% for all rapid tests. Compared with the IgM-sensitive EIA, rapid tests gave false-negative results with an additional 2-5 specimens. All rapid tests had statistically equivalent performance characteristics, based on overlapping confidence intervals for sensitivity and specificity, compared with either conventional EIA. CONCLUSIONS: All 6 rapid tests have high sensitivity and specificity, compared with that of conventional EIAs. Because performance was similar for all tests and specimen types, other characteristics, such as convenience, time to result, shelf life, and cost will likely be determining factors for selection of a rapid HIV screening test for a specific application.
BACKGROUND: Since 2002, the US Food and Drug Administration has approved 6 rapid human immunodeficiency virus (HIV) tests for use in the United States. To date, there has been no direct comparison of the performance of all 6 tests. METHODS:Persons known to be HIV-infected and persons who sought HIV testing at 2 clinical sites in Los Angeles, California, were recruited for evaluation of 6 rapid HIV tests with whole blood, oral fluid, serum, and plasma specimens. Sensitivity and specificity of the rapid tests were compared with viral lysate and immunoglobulin (Ig) M-sensitive peptide HIV enzyme immunoassays (EIAs). RESULTS: A total of 6282 specimens were tested. Sensitivity was >95% and specificity was >99% for all rapid tests. Compared with the IgM-sensitive EIA, rapid tests gave false-negative results with an additional 2-5 specimens. All rapid tests had statistically equivalent performance characteristics, based on overlapping confidence intervals for sensitivity and specificity, compared with either conventional EIA. CONCLUSIONS: All 6 rapid tests have high sensitivity and specificity, compared with that of conventional EIAs. Because performance was similar for all tests and specimen types, other characteristics, such as convenience, time to result, shelf life, and cost will likely be determining factors for selection of a rapid HIV screening test for a specific application.
Authors: Pragna Patel; Berry Bennett; Timothy Sullivan; Monica M Parker; James D Heffelfinger; Patrick S Sullivan Journal: J Clin Virol Date: 2012-02-29 Impact factor: 3.168
Authors: Yen T Duong; Yvonne Mavengere; Hetal Patel; Carole Moore; Julius Manjengwa; Dumile Sibandze; Christopher Rasberry; Charmaine Mlambo; Zhi Li; Lynda Emel; Naomi Bock; Jan Moore; Rejoice Nkambule; Jessica Justman; Jason Reed; George Bicego; Dennis L Ellenberger; John N Nkengasong; Bharat S Parekh Journal: J Clin Microbiol Date: 2014-08-13 Impact factor: 5.948
Authors: Laura Wesolowski; Pollyanna Chavez; Patrick Sullivan; Arin Freeman; Akshay Sharma; Brian Mustanski; A D McNaghten; Robin MacGowan Journal: AIDS Behav Date: 2019-04
Authors: Iris Chen; Vanessa Cummings; Jessica M Fogel; Mark A Marzinke; William Clarke; Matthew B Connor; Sam Griffith; Susan Buchbinder; Steven Shoptaw; Carlos Del Rio; Manya Magnus; Sharon Mannheimer; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Michael B Blank; Seth S Himelhoch; Alexandra B Balaji; David S Metzger; Lisa B Dixon; Charles E Rose; Emeka Oraka; Annet Davis-Vogel; William W Thompson; James D Heffelfinger Journal: Am J Public Health Date: 2014-02-13 Impact factor: 9.308
Authors: Ronald M Galiwango; Richard Musoke; Lawrence Lubyayi; Robert Ssekubugu; Sarah Kalibbala; Viola Ssekweyama; Viola Mirembe; Gertrude Nakigozi; Steven J Reynolds; David Serwadda; Ronald H Gray; Godfrey Kigozi Journal: J Virol Methods Date: 2013-04-11 Impact factor: 2.014
Authors: Kevin P Delaney; Jacqueline Rurangirwa; Shelley Facente; Teri Dowling; Mike Janson; Thomas Knoble; Annie Vu; Yunyin W Hu; Peter R Kerndt; Jan King; Susan Scheer Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731